Based in Taipei, Taiwan, Ancheng Biotech has developed an AC-1101 drug for treating inflammatory skin diseases like vitiligo. They also offer an AC-201 oral small molecule drug that inhibits the polymerization of NLRP3 inflammasomes, reducing the activity of pro-inflammatory cytokines. Their products have potential applications in treating various inflammatory and autoimmune diseases such as rheumatoid arthritis, osteoarthritis, gout, and type 2 diabetes. Ancheng Biotech aims to provide safe and effective new drugs to patients worldwide by re-positioning existing drug molecules and addressing unmet medical needs.